若生智能
Drug Database
CA

cannabidiol (Xalex 10)

✓ Approved

RAMM Pharma · CNR1

什么是 cannabidiol？

cannabidiol 是一种治疗药物，由RAMM Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Xalex 10
公司RAMM Pharma
分子靶点CNR1, TRPV1, GPR55
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, RAMM Pharma

作用机制

分子靶点

cannabidiol 作用于 3 个分子靶点：

CNR1cannabinoid receptor 1 (CNR, CB1A)
TRPV1transient receptor potential cation channel subfamily V member 1 (VR1)
GPR55G protein-coupled receptor 55 (LPIR1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cannabidiol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersEpilepsy✓ Approved

相关研究文献

PubMedJournal of the American Chemical Society2026-07-27

Chiral Phosphoric Acid-Catalyzed Asymmetric Hydrogenolysis of C-O Bonds.

Xie Qing-Xian QX, Chen Jia-Yi JY, Wang Gao-Wei GW, Li Xiang X et al.

The combination of chiral phosphoric acid with a biomimetic hydrogen source (Hantzsch esters) constitutes a powerful system for asymmetric reduction of unsaturated compounds. In contrast, asymmetric hydrogenolysis of C-O single bonds remains an elusive challenge owing to the high C-O bond energy and the weak intermolecular affinity between the substrate and the catalyst. In this study, we report a hydrogen-bond-activation strategy, driven by aromatization, for asymmetric hydrogenolysis of C-O bonds using the chiral phosphoric acid/Hantzsch ester system. This protocol enables kinetic resolution of o-quinone monoketals, affording axially chiral compounds and chiral spirocycles with selectivity factors up to 1773. Moreover, this methodology provides an efficient route to axially chiral cannabidiol (axCBD) analogs. Preliminary mechanistic experiments and DFT calculations suggested that asymmetric hydrogenolysis proceeded via an enantioselective 1,4-transfer hydrogenation initiation step, followed by an aromatization-driven remote proton transfer and skeletal rearrangement.

PMID 42504750
阅读全文 →
PubMedClinical toxicology (Philadelphia, Pa.)2026-07-27

Serum cannabinoid profiles of emergency department patients presenting with cannabinoid hyperemesis syndrome and acute cannabis intoxication.

Toomey David D, Merchant-Borna Kian K, Krotulski Alex J AJ, Baker Savannah S et al.

The underlying pathophysiology of cannabinoid hyperemesis syndrome remains poorly understood. Proposed mechanisms include "hyperintoxication" with delta-9-tetrahydrocannabinol, accumulation of delta-9-tetrahydrocannabinol metabolites, and differential exposure to non-psychotropic phytocannabinoids. This study sought to examine quantitative differences in serum concentrations of delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabinol metabolites, delta-8-tetrahydrocannabinol, and common non-psychotropic phytocannabinoids between patients presenting to the emergency department with either acute, symptomatic cannabinoid hyperemesis syndrome or acute cannabis intoxication. This was a retrospective cohort study performed in the emergency department of a single academic medical center. Subjects were screened based on discharge diagnosis consistent with either cannabinoid hyperemesis syndrome or acute cannabis intoxication and on availability of remnant blood samples. Chart data including emergency department length of stay, disposition, treatment, and labs were abstracted, and blood samples were analyzed via liquid chromatography-triple quadrupole tandem mass spectrometry for serum concentrations of delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydrocannabinol, delta-8-carboxy-tetrahydrocannabinol, cannabidiol, cannabigerol, and cannabinol. Fifty subjects were enrolled; thirty-five presented with cannabinoid hyperemesis syndrome and 15 with acute cannabis intoxication. Groups were well matched with regard to baseline demographics, emergency department disposition, and emergency department length of stay. No significant differences were noted in serum concentrations of delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabinol metabolites, non-psychotropic phytocannabinoids, or their respective ratios. While limited by uncontrolled host factors, the results of this study further existing literature arguing against the differential accumulation of psychoactive cannabinoids, non-psychoactive cannabinoids, or their metabolites as causative factors in the development of acute symptomatic episodes of cannabinoid hyperemesis syndrome. There does not appear to be a significant difference in concentrations of psychoactive and non-psychoactive cannabinoids between emergency department patients with symptomatic cannabinoid hyperemesis syndrome and those with acute cannabis intoxication.

PMID 42504769
阅读全文 →
PubMedFrontiers in neuroimaging2026-07-24

Functional neuroimaging of Cannabidiol in stress and anxiety: a systematic review.

Rutledge Omar O, Goyette Richard B RB, Wang Kimberly L KL, Park Madelynn S MS et al.

Cannabidiol (CBD) is a non-intoxicating phytocannabinoid primarily derived from hemp (cannabis sativa L.) that has been investigated for its potential anxiolytic effects. Prior functional neuroimaging studies suggest that CBD may affect brain regions associated with stress and anxiety. However, it remains unclear if there is a consistent pattern of modulation within these regions and if there is a correlation with behavioral or physiological measures. We conducted a systematic review examining adult human neuroimaging investigations comparing CBD with placebo under conditions related to stress or anxiety. We searched PubMed, Web of Science, EBSCO, and ProQuest for studies published before June 30, 2025. The quality of the evidence was assessed with the revised Cochrane Risk of Bias Tool for Randomized Trials (RoB 2), findings were summarized using a Synthesis Without Meta-analysis (SWiM) approach, and certainty of evidence was rated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. A total of 12 studies with 146 participants in 7 cohorts met the eligibility criteria and were included in the synthesis. Results indicated a wide distribution of reported peaks across many cortical and subcortical regions with mixed directions of activation or perfusion, demonstrating substantial heterogeneity in the reported findings. Risk of bias assessments generally indicated either some concerns or high risk of bias, and the certainty of evidence was judged to be low to very low. Overall, there is a lack of consistent evidence showing the acute effects of CBD on the brain across various study designs. The current literature on the putative anxiolytic effects of CBD is constrained by methodological variability and limited statistical power. Future studies should employ standardized paradigms, improve reporting practices, and include more diverse and adequately powered samples to clarify the neural correlates of CBD-related effects on stress and anxiety. PROSPERO, CRD420251063369.

PMID 42494831
阅读全文 →
PubMedVeterinary world2026-07-24

Preclinical antitumor evaluation of a tetrahydrocannabinol and cannabidiol (1:6) cannabis extract in an MCF-7 xenograft model of estrogen receptor-positive breast cancer.

Meesiripan Nuntana N, Thanasitthichai Somchai S, Sangrajrang Suleeporn S, Suwanpidokkul Nuntakan N et al.

Breast cancer remains one of the leading causes of cancer-related mortality worldwide, despite advances in surgery, chemotherapy, endocrine therapy, and targeted treatments. Cannabinoids derived from Cannabis sativa, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), have demonstrated anticancer properties in several experimental models; however, in vivo evidence in estrogen receptor (ER)-positive breast cancer remains limited. This study aimed to evaluate the antitumor effects of a THC:CBD (1:6) cannabis extract in a Michigan Cancer Foundation-7 breast cancer cell line (MCF-7) xenograft mouse model of ER-positive breast cancer. Female BALB/c nude mice bearing MCF-7 xenograft tumors were randomly assigned into five groups (n = 5/group): negative control (sesame oil), positive control treated with 5-fluorouracil (5-FU; 20 mg/kg), and three treatment groups receiving oral THC:CBD (1:6) extract at doses of 2, 10, or 20 mg/kg body weight for 30 consecutive days. Tumor growth was monitored throughout the experiment. Histopathological examination and immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) expression were performed to evaluate apoptosis-related morphology and tumor cell proliferation. Hematological and biochemical parameters were assessed to determine systemic safety. Cannabinoid-treated groups exhibited significant suppression of tumor growth compared with the negative control group. Tumor volume reduction was observed in all treatment groups, with the greatest reduction detected in the high-dose THC:CBD group. Histopathological evaluation revealed increased numbers of tumor cells exhibiting morphological features consistent with apoptosis in cannabinoid-treated mice. Immunohistochemical analysis demonstrated significantly lower PCNA expression scores in all THC:CBD-treated groups compared with both negative and positive controls, indicating reduced tumor cell proliferation. Hematological parameters remained within normal physiological ranges in cannabinoid-treated animals. However, elevated alanine aminotransferase and aspartate aminotransferase levels were observed in the high-dose group, suggesting potential dose-related hepatic stress. The THC:CBD (1:6) cannabis extract demonstrated significant antitumor activity in an MCF-7 xenograft model by suppressing tumor progression primarily through inhibition of tumor cell proliferation, with supportive apoptosis-related histological features. These findings provide novel in vivo evidence supporting the potential of cannabinoid-based formulations as adjunctive therapeutic approaches for ER-positive breast cancer.

PMID 42494695
阅读全文 →
PubMedACS omega2026-07-24

Cannabis Sativa L. Hemp Hurd Biochar: Influence of Pyrolysis Conditions on Carbonization and Residual Volatile Organic Compounds.

Patterson Gabriel D GD, Olajide Samuel S, Hafez Islam I, Karman Andrew A et al.

Cannabis sativa L. (hemp) is increasingly recognized not only as an agricultural commodity for textile fibers and cannabidiol (CBD) products but also as a platform for domestic innovation in biobased materials. Hemp hurd (HH), the woody inner core of the hemp stalk, is a fibrous, carbon-rich (∼50 wt %) lignocellulosic biomass with potential for conversion into value-added biochar. Herein, HH-derived biochar was investigated with emphasis on how pyrolysis conditions influence yield, carbonization, structure, and residual volatile organic compounds (VOCs). The effects of temperature (250-650 °C), residence time (15-60 min), particle size (1.0-12.7 mm), and sample mass (5.0-20.0 g) were evaluated. HH biochar structure was characterized by Raman spectroscopy, while residual VOCs associated with a representative high-loading condition were analyzed using headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry (HS-SPME/GC-MS). Within the resolution of the data set, reduced particle size and temperatures ≥550 °C were associated with enhanced carbonization and greater structural ordering, while increased biomass loading at fixed reactor volume led to elevated apparent biochar yields consistent with partial retention of condensable species. Biochar produced at ≥550 °C exhibited low H/C ratios (∼0.20) and aromatic carbon structures indicative of extensive carbonization. These results guide rational optimization and scale-up of HH-derived biochar production.

PMID 42495410
阅读全文 →
PubMedDrug delivery2026-07-23

Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.

Muta Thabata T, Mukhopadhyay Songhita S, Noll Benjamin B, Song Yunmei Y et al.

Cannabidiol (CBD) exhibits poor oral bioavailability (approximately 6%) due to low solubility and excessive first-pass metabolism, limiting its therapeutic potential. This study introduces a novel phospholipid complex self-nanoemulsifying drug delivery system (CBD-PLC-SNEDDS) to enhance CBD delivery. CBD-PLC was integrated into an optimized SNEDDS via Design of Experiments (DoE), yielding nanoemulsions with 118.9 ± 0.77 nm particle size, 0.258 PDI, and -21.9 mV zeta potential. Physicochemical characterization (DSC, FTIR) confirmed amorphization and physical encapsulation without chemical alteration. In vitro dissolution showed 100% CBD release within 1 h for CBD-PLC-SNEDDS vs. 8 h for CBD-SNEDDS. Stability studies (ICH guidelines) retained 94.73% ± 0.62% CBD at 25 °C/60% RH and 80.21% ± 0.61% at 40 °C/75% RH after 4 months with preservatives. In vivo pharmacokinetics in Sprague-Dawley rats (n = 9, 20 mg/kg oral; 4 mg/kg IV) demonstrated that CBD-PLC-SNEDDS significantly enhanced systemic exposure, achieving a calculated absolute bioavailability (F) of 92%, compared to 47% for the oleic acid control. The formulation yielded a 5-fold higher C max (593 ± 246 vs 118 ± 63 ng/mL) doubled AUC0-∞ (88 vs. 45 h·kg·ng/mL/mg), faster T max (2 ± 0.3 vs. 7.4 ± 2.3 h), and extended T 1/2 (3.7 ± 0.9 vs. 1.9 ± 0.6 h) versus control. CBD-PLC alone yielded only 39%. IVIVC modelling via Wagner-Nelson deconvolution established a strong correlation (R2 > 0.7) between in vitro dissolution and in vivo absorption, validating the system's predictive performance. This synergistic PLC-SNEDDS platform outperforms prior systems, offering a scalable template for lipophilic drugs and paving the way for clinical CBD therapeutics.

PMID 42487275
阅读全文 →

注册免费账户还可查看另外 7845 篇文献

免费注册查看全部文献 →

了解更多cannabidiol